Literature DB >> 27527091

Serum activities of adenosine deaminase, dipeptidyl peptidase IV and prolyl endopeptidase in patients with fibromyalgia: diagnostic implications.

Ognjen Čulić1, Mario D Cordero2, Tihana Žanić-Grubišić3, Anita Somborac-Bačura3, Lara Batičić Pučar4, Dijana Detel4, Jadranka Varljen4, Karmela Barišić3.   

Abstract

Fibromyalgia (FM) is a chronic pain syndrome with number of symptoms that present challenge in terms of diagnosis and treatment. Patients with FM show abnormal profile of purines in plasma. In this work, we measured serum activities of enzymes involved in purine metabolism, namely total adenosine deaminase (ADE) and its isoforms (ADE1 and ADE2), ecto-ATPase, and 5'-nucleotidase (5'-NT). We also measured activity of dipeptidyl peptidase IV (DPPIV) and prolyl endopeptidase (PEP). Spectrophotometric and fluorometric methods were used for enzyme activity determinations. Enzyme activities were measured in sera of 24 patients with FM that were not undergoing pharmacological treatment during the study. Control group comprised 32 healthy control subjects. Significantly higher activities of total ADE (P = 0.025) and ADE2 (P = 0.011) were observed in FM patients, while no significant differences in ADE1, ecto-ATPase, and 5'-NT activities (P > 0.05) were found when compared to healthy controls. Moreover, increase in the activity of DPPIV (P = 0.015) and lower activity of PEP (P = 0.011) were also found in the FM group. ROC analysis pointed to different diagnostic sensitivities/specificities for individual enzyme activities measured as follows: ADE (50.0/87.5), ADE2 (41.7/90.6), DPPIV (62.5/71.9), and PEP (83.3/62.5). ADE2 and PEP were shown to be independent predictors of FM, while combination of the two gives AUC of 0.786 (95 % confidence interval of 0.656-0.885, P < 0.05). Our results are showing that serum activities of ADE2 and PEP could be useful as biomarkers for FM diagnosis. However, relatively low diagnostic sensitivity of ADE2 and specificity of PEP must be taken into account.

Entities:  

Keywords:  Adenosine; Diagnostic biomarker; Fibromyalgia; Serum enzymes

Mesh:

Substances:

Year:  2016        PMID: 27527091     DOI: 10.1007/s10067-016-3377-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  15 in total

1.  High cell surface CD26-associated activities and low plasma adenosine concentration in fibromyalgia.

Authors:  Régis Guieu; Eric Guedj; Roch Giorgi; Alix Dousset; Veronique Tuzzolino; Youlet By; Jean Marc Leveque; Jean Claude Peragut; Jean Régis; Jean Ruf; Emmanuel Fenouillet; Philippe Roussel
Journal:  Ann Rheum Dis       Date:  2012-04-13       Impact factor: 19.103

2.  New American College of Rheumatology criteria for fibromyalgia: a twenty-year journey.

Authors:  Frederick Wolfe
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

3.  IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients.

Authors:  Danelia Mendieta; Dora Luz De la Cruz-Aguilera; Maria Isabel Barrera-Villalpando; Enrique Becerril-Villanueva; Rodrigo Arreola; Erick Hernández-Ferreira; Sonia Mayra Pérez-Tapia; Gilberto Pérez-Sánchez; María Eugenia Garcés-Alvarez; Lucinda Aguirre-Cruz; Marco Antonio Velasco-Velázquez; Lenin Pavón
Journal:  J Neuroimmunol       Date:  2015-11-26       Impact factor: 3.478

Review 4.  Adenosine in the spinal cord and periphery: release and regulation of pain.

Authors:  Jana Sawynok; Xue Jun Liu
Journal:  Prog Neurobiol       Date:  2003-04       Impact factor: 11.685

Review 5.  Roles of adenosine and its receptors in sleep-wake regulation.

Authors:  Zhi-Li Huang; Ze Zhang; Wei-Min Qu
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

6.  Purine metabolites in fibromyalgia syndrome.

Authors:  A Fais; E Cacace; M Corda; B Era; M Peri; S Utzeri; V Ruggiero
Journal:  Clin Biochem       Date:  2012-09-18       Impact factor: 3.281

7.  Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients.

Authors:  Suncica Buljevic; Dijana Detel; Lara Baticic Pucar; Radovan Mihelic; Tomislav Madarevic; Branko Sestan; Jadranka Varljen
Journal:  Rheumatol Int       Date:  2013-07-18       Impact factor: 2.631

Review 8.  The dipeptidyl peptidase IV family in cancer and cell biology.

Authors:  Denise M T Yu; Tsun-Wen Yao; Sumaiya Chowdhury; Naveed A Nadvi; Brenna Osborne; W Bret Church; Geoffrey W McCaughan; Mark D Gorrell
Journal:  FEBS J       Date:  2010-01-13       Impact factor: 5.542

9.  The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee.

Authors:  F Wolfe; H A Smythe; M B Yunus; R M Bennett; C Bombardier; D L Goldenberg; P Tugwell; S M Campbell; M Abeles; P Clark
Journal:  Arthritis Rheum       Date:  1990-02

10.  Prolyl endopeptidase activity is correlated with colorectal cancer prognosis.

Authors:  Gorka Larrinaga; Itxaro Perez; Lorena Blanco; Begoña Sanz; Peio Errarte; Maider Beitia; María C Etxezarraga; Alberto Loizate; Javier Gil; Jon Irazusta; José I López
Journal:  Int J Med Sci       Date:  2014-01-10       Impact factor: 3.738

View more
  1 in total

1.  Ambroxol for the treatment of fibromyalgia: science or fiction?

Authors:  Kai-Uwe Kern; Myriam Schwickert
Journal:  J Pain Res       Date:  2017-08-16       Impact factor: 3.133

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.